A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
Cybulski C, Huzarski T, Górski B, Masojć B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, Złowocka E, Kurzawski G, Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, Lubiński J.
Cybulski C, et al. Among authors: lubinski j.
Cancer Res. 2004 Apr 15;64(8):2677-9. doi: 10.1158/0008-5472.can-04-0341.
Cancer Res. 2004.
PMID: 15087378